Hematopoietic stem cell gene therapy is potentially curative for a number of inherited and acquired disorders. However, poor gene transfer and expression in repopulating hematopoietic stem cells attenuate this potential. Here we review potential means of conferring a selective advantage to hematopoietic stem cells and their progeny, and discuss the issues that surround the use of selective advantages in vivo.
No takes yet. Share an insight, caveat, or question.
Milsom et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: